Among other factors, the distribution of some $5 trillion of pandemic stimulus likely compelled the Federal Reserve to enact monetary policy to counter inflation. If financial tightening persists, investors might be urged to consider the long-term implications for the stock market in today’s post-pandemic world.
Transferring currency across international borders is often met with various hurdles, especially for those in emerging markets. In this article, investing columnist Aditi Somayajula explains some of these challenges, as well as how fintech companies are attempting to streamline different aspects of cross-border payments.
Last year, investor sentiment suggested that South Korean e-commerce giant Coupang would come to parallel the success of Amazon or the Alibaba Group. But since then, optimism has fallen. In this article, Investing Columnist Aditi Somayajula explains how, in the absence of a sustainable profitability model, Coupang might fare in the long term.
For decades, drug discovery has been known to be an immense investment with low odds of success. The costs of research and development (R&D) alone are notably high, averaging out to be $1.3 billion per drug in the United States. And yet, despite this funding, out of the tens of thousands of drug candidates that seek approval by the FDA each year, generally only 40 to 50 are successful. Life sciences company Schrödinger is attempting to expedite this process.
MercadoLibre is commonly referred to as the ‘Amazon of Latin America.’ Both an online marketplace and a payments platform, the company operates in a region with tremendous potential, one that has yet to undergo a digital transformation of retail. In this article, Community columnist Aditi Somayajula explains why MercadoLibre is one to watch.
Last year, Google-owned DeepMind solved the decades-long protein folding problem with an elegant AI approach, fundamentally improving our understanding of our own biology. In this article, Community columnist Aditi Somayajula explains the science behind DeepMind’s solution and explores how big tech is likely to become the new big pharma.
For decades, the American housing industry has remained relatively resistant to change. But amidst the current housing climate, proptech companies, tech startups in the real estate space, have begun to streamline different aspects of the industry. This article will present a case for proptech and its ability to reinvent real estate.